Literature DB >> 15719225

HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice.

N Eser Ercil1, Ruggero Galici, Robert A Kesterson.   

Abstract

RATIONALE: Melanocortin and opioid systems regulate feeding as well as other behaviors; however, the relationship between the two systems is not yet defined. Since agonist-induced stimulation of melanocortin receptors blocks the behavioral effects of mu opioid receptor agonists, and melanocortin-4 (MC4) receptors and mu opioid receptors share a similar anatomical distribution in the central nervous system, MC4 receptor blockade may increase opioid responsiveness.
OBJECTIVES: The goal of this study was to test the hypothesis that blockade of MC4 receptors increases the behavioral effects of morphine.
METHODS: The effects of HS014 (0.0032, 0.032, and 1 nmol, i.c.v.), a selective MC4 antagonist, on morphine-induced (3.2, 10, and 32 mg/kg, i.p.) locomotor activity (measured in the open field for 15 min) and antinociception (measured in the hot plate at 55 degrees C) were assessed in C57Bl/6 mice. In addition, the effects of morphine were evaluated in A(y) mice, a genetic model for MC4 receptor blockade.
RESULTS: The dose-effect curve of morphine for locomotor activity was shifted downwards in C57Bl/6 mice pretreated with HS014 and in A(y) mice. The dose-effect curve of morphine for antinociception was shifted two- and threefold to the left in C57Bl/6 mice pretreated with HS014 and in A(y) mice, respectively.
CONCLUSIONS: These results indicate that blockade of MC4 receptors increases the antinociceptive effects of morphine without changing the potency of morphine for locomotor activity, suggesting that MC4 receptor antagonists may be candidate drugs that can be clinically used for the treatment of pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719225     DOI: 10.1007/s00213-005-2166-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

Review 1.  Chronic opioid therapy for non-cancer pain.

Authors:  B J Collett
Journal:  Br J Anaesth       Date:  2001-07       Impact factor: 9.166

Review 2.  Melanocortins and opiate addiction.

Authors:  J D Alvaro; J B Tatro; R S Duman
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

3.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

Review 4.  Neuropathic pain: a possible role for the melanocortin system?

Authors:  D H Vrinten; C J Kalkman; R A Adan; W H Gispen
Journal:  Eur J Pharmacol       Date:  2001-10-19       Impact factor: 4.432

Review 5.  Melanocortins and the brain: from effects via receptors to drug targets.

Authors:  R A Adan; W H Gispen
Journal:  Eur J Pharmacol       Date:  2000-09-29       Impact factor: 4.432

6.  Interaction between the spinal melanocortin and opioid systems in a rat model of neuropathic pain.

Authors:  Dorien H Vrinten; Willem Hendrik Gispen; Cor J Kalkman; Roger A H Adan
Journal:  Anesthesiology       Date:  2003-08       Impact factor: 7.892

7.  Differential influence of a selective melanocortin MC4 receptor antagonist (HS014) on melanocortin-induced behavioral effects in rats.

Authors:  A V Vergoni; A Bertolini; F Mutulis; J E Wikberg; H B Schiöth
Journal:  Eur J Pharmacol       Date:  1998-12-04       Impact factor: 4.432

8.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

9.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor.

Authors:  D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

10.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain.

Authors:  K G Mountjoy; M T Mortrud; M J Low; R B Simerly; R D Cone
Journal:  Mol Endocrinol       Date:  1994-10
View more
  14 in total

1.  Deletion of agouti-related protein blunts ethanol self-administration and binge-like drinking in mice.

Authors:  M Navarro; I Cubero; L Ko; T E Thiele
Journal:  Genes Brain Behav       Date:  2009-06       Impact factor: 3.449

2.  Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.

Authors:  Montserrat Navarro; Francisca Carvajal; Jose Manuel Lerma-Cabrera; Inmaculada Cubero; Mitchell J Picker; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2015-06-24       Impact factor: 3.455

Review 3.  Synaptic changes induced by melanocortin signalling.

Authors:  Vanni Caruso; Malin C Lagerström; Pawel K Olszewski; Robert Fredriksson; Helgi B Schiöth
Journal:  Nat Rev Neurosci       Date:  2014-02       Impact factor: 34.870

4.  Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice.

Authors:  Montserrat Navarro; Kendall L Luhn; Alexey B Kampov-Polevoy; James C Garbutt; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2019-03-19       Impact factor: 3.455

5.  Control of food intake by MC4-R signaling in the lateral hypothalamus, nucleus accumbens shell and ventral tegmental area: interactions with ethanol.

Authors:  Jose M Lerma-Cabrera; Francisca Carvajal; Lourdes de la Torre; Leticia de la Fuente; Montserrat Navarro; Todd E Thiele; Inmaculada Cubero
Journal:  Behav Brain Res       Date:  2012-06-17       Impact factor: 3.332

6.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

7.  Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Authors:  Daniele Vicari; Kevin C Foy; Eric M Liotta; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

8.  Ethanol-induced increase of agouti-related protein (AgRP) immunoreactivity in the arcuate nucleus of the hypothalamus of C57BL/6J, but not 129/SvJ, inbred mice.

Authors:  Inmaculada Cubero; Montserrat Navarro; Francisca Carvajal; Jose Manuel Lerma-Cabrera; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2010-01-26       Impact factor: 3.455

9.  Addiction and the adrenal cortex.

Authors:  Gavin P Vinson; Caroline H Brennan
Journal:  Endocr Connect       Date:  2013-05-31       Impact factor: 3.335

Review 10.  The melanocortin system as a potential target for treating alcohol use disorders: A review of pre-clinical data.

Authors:  José Manuel Lerma-Cabrera; Francisca Carvajal; James C Garbutt; Montserrat Navarro; Todd E Thiele
Journal:  Brain Res       Date:  2019-12-28       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.